NEWS
Norameda in Latvia: stable growth from year to year despite crises affecting Europe
"It has been a great year marked by high sales; we managed to achieve our strategic goals. As a result, I expect around 20% growth by the end of the financial year," says Ervins Groms, leading the Norameda branch in Latvia. The oncology line was the main contributor...
World COPD Day 2022: time to raise awareness and share knowledge
Around 3 million people die from Chronic Obstructive Pulmonary Disease (COPD) every year. It is estimated that 4-6% of men and 1-3% of women have COPD, though the exact prevalence of COPD is unknown. COPD is the fourth most common cause of death in many countries. And...
The war impact on the CEE market and the uniqueness of the Baltics
A few weeks ago, we presented the global pharmaceutical market review. This time, we would like to update you on trends in EC Europe and the Baltics in particular. The impact of War First and foremost, the war in Ukraine is having a significant impact on the region....
Estimated growth slowdown in the largest therapy areas and new consuming trends
We at Norameda aim to keep a finger on the pharmaceutical market pulse and share the knowledge with our partners. So here are the latest statistics and trends. Oncology sales on increase According to the latest statistics, the main trends remain: oncology ($184 bn)...